||
Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
AZD9291 shows significantly more potent inhibition of proliferation in mutant EGFR cell lines compared to wild-type in vitro. [2]
AZD9291(5mg/kg p.o.) causes profound regression of tumors across EGFRm+ (PC9) and EGFRm+/T790M (H1975) tumor models with profound inhibition of EGFR phosphorylation and key downstream signaling pathways such as AKT and ERK in vivo. [2]
References
[1] Patent. 2013, WO2013014448 A1.
[2] Cross, et al. Mol Cancer Ther. 2013, 12, A109.
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-10-8 05:40
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社